Basic Information

Gene symbol S Synonyms E2 Type of gene protein-coding
Gene perturbation-related omics dataset PerturbAtlas
Description spike glycoprotein

GTO ID GTC3493
Trial ID NCT05925127
Disease COVID-19
Altered gene S
Therapeutic/Target gene Therapeutic gene
TherapymRNA vaccine
Treatment NVX-CoV2373|NVX-CoV2601|Bivalent XBB.1.5
PhasePhase2|Phase3
Recruitment statusRecruiting
TitleA Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults ≥ 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines
Year2023
CountryUnited States
Company sponsorNovavax
Other ID(s)2019nCoV-205

Clinical Result

Cohort1: NVX-CoV2373
Administration route intramuscular injection
Dosage antigen, 5μg; Matrix-M, 50μg
Pts 198
Age Adult, Older_Adult
Cohort2: NVX-CoV2601_antigen_dose level 1_adjuvant_dose level 1
Administration route intramuscular injection
Dosage antigen, 5μg; Matrix-M, 50μg
Pts 396
Age Adult, Older_Adult
Cohort3: NVX-CoV2601_antigen_dose level 1_adjuvant_dose level 2
Administration route intramuscular injection
Dosage antigen, 5μg; Matrix-M, 75μg
Pts 396
Age Adult, Older_Adult
Cohort4: NVX-CoV2601_antigen_dose level 2_adjuvant_dose level 1
Administration route intramuscular injection
Dosage antigen, 35μg; Matrix-M, 50μg
Pts 396
Age Adult, Older_Adult
Cohort5: NVX-CoV2601_antigen_dose level 2_adjuvant_dose level 2
Administration route intramuscular injection
Dosage antigen, 35μg; Matrix-M, 75μg
Pts 396
Age Adult, Older_Adult
Cohort6: NVX-CoV2601_antigen_dose level 3_adjuvant_dose level 3
Administration route intramuscular injection
Dosage antigen, 50μg; Matrix-M, 100μg
Pts 198
Age Adult, Older_Adult
Cohort7: Bivalent BA.4/5
Administration route intramuscular injection
Pts 180
Age Adult, Older_Adult

Relationship Graph

Overview of Knowledge Graph